I. Hardan et al., INHIBITION OF METASTATIC CELL COLONIZATION IN MURINE LUNGS AND TUMOR-INDUCED MORBIDITY BY NONPEPTIDIC ARG-GLY-ASP MIMETICS, International journal of cancer, 55(6), 1993, pp. 1023-1028
The spreading and colonization of tumor cells require their migration
to metastatic sites via blood vessels. To penetrate blood-vessel walls
, cells, including malignant ones, must recognize and associate with t
he sub-endothelium extracellular matrix (ECM) and its glycoproteins. R
ecognition of ECM-glycoproteins, such as fibronectin (FN) and vitronec
tin (VN), is mediated by integrin receptors expressed on various cell
types, including platelets, leukocytes and tumor cells. The Arg-Gly-As
p (RGD)-containing peptide, a major adhesive ligand of ECM, is present
in various plasma and matrix glycoproteins, such as FN and VN. Non-pe
ptidic mimetics of RGD, consisting of carboxylate and guanidinium grou
ps of Asp and Arg divided by a linear atom spacer, express a high affi
nity for the alpha(IIb)-beta3 integrin and inhibit platelet aggregatio
n. Herein, the ability of RGD mimetics to inhibit adhesive interaction
s between tumor cells and RGD, and tumor progression in vivo, was exam
ined. RGD-containing peptides and the RGD mimetic, compound SF-6,5, bu
t not the Arg-Gly-Glu (RGE) peptide or the corresponding mimetic, spec
ifically inhibited B16-F10 melanoma cell adhesion to immobilized VN an
d FN. Daily administration in vivo of SF-6,S to mice inhibited the for
mation of B16-F10 colonies in experimental and spontaneous models of m
etastases. Moreover, SF-6,5 could prevent mouse death caused by massiv
e colonization of tumor cells in the lungs. The therapeutic effect of
RGD-containing peptides on tumor metastasis formation was marginal, pr
obably due to the small amounts used, and its susceptibility to proteo
lysis in situ. Thus, non-peptidic mimetics of small adhesive epitopes
may provide a novel therapeutic tool to prevent an adverse pathologica
l event involving integrin-dependent cell-cell and cell-ECM interactio
ns. (C) 199-3 Wiley-Liss, Inc.